AVEO Oncology (NSDQ:AVEO) announced today that it entered into a clinical trial collaboration with Bristol Myers Squibb. Boston-based AVEO’s collaboration and supply agreement with Bristol Myers Squibb is slated to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab), an anti-PD-1 therapy developed by Bristol Myers Squibb. The drugs will be evaluated in a pivotal Phase […]
AVEO Oncology
AVEO Oncology names new chief commercial officer
AVEO Oncology (NSDQ:AVEO) announced that it appointed Mike Ferraresso as its new chief commercial officer. Boston-based AVEO Oncology said in a news release that Feraresso will manage the company’s commercial strategy and operations, including the commercialization of Fotivda (tivozanib), a differentiated, oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). Fotivda is […]
